Open access
Open access
Powered by Google Translator Translator

Covid-19

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

2 Jul, 2021 | 11:39h | UTC

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations – British Journal of Haematology

Commentary: Blood clots related to AstraZeneca/Oxford vaccine can be mitigated with early detection – MedicalXpress

 

Delirium in COVID-19: can we make the unknowns knowns?

2 Jul, 2021 | 11:17h | UTC

Delirium in COVID-19: can we make the unknowns knowns? – Intensive Care Medicine

 

Commentary on Twitter

 

[Press release] J&J single-shot COVID-19 vaccine generates strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.

2 Jul, 2021 | 11:38h | UTC

Press release: Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Commentary: J&J Covid Shot Neutralizes Delta Variant, Company Says – Bloomberg (a few articles per month are free)

 

COVID-19 vaccines reduce severity, length, viral load for those who still get infected.

1 Jul, 2021 | 09:57h | UTC

COVID-19 vaccine reduces severity, length, viral load for those who still get infected – University of Arizona Health Sciences

Original study: Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines – New England Journal of Medicine

 

Commentary on Twitter

 

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

1 Jul, 2021 | 09:59h | UTC

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine – New England Journal of Medicine

Audio interview: Audio Interview: Another New Covid-19 Vaccine – New England Journal of Medicine

Related: Opinion | The mRNA vaccines are extraordinary, but Novavax is even better

 

Analysis: How long does covid-19 immunity last?

1 Jul, 2021 | 09:56h | UTC

How long does covid-19 immunity last? – The BMJ

 

The neurological manifestations of post-acute sequelae of SARS-CoV-2 infection.

1 Jul, 2021 | 09:55h | UTC

The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection – Current Neurology and Neuroscience Reports

 

Systematic review: Border controls, restricted entry, quarantine essential for curbing COVID-19 and future pandemics.

1 Jul, 2021 | 09:53h | UTC

News release: Border controls, restricted entry, quarantine essential for curbing COVID-19 and future pandemics – British Medical Journal

Original study: Lessons from countries implementing find, test, trace, isolation and support policies in the rapid response of the COVID-19 pandemic: a systematic review – BMJ Open

Commentary: Strategies ID’d Than Can Interrupt Spread of Infectious Disease – HealthDay

 

Perspective | Why no one is sure if Delta is deadlier – “The variants are spreading faster, but they don’t necessarily have incentive to kill more often”.

1 Jul, 2021 | 09:52h | UTC

Why No One Is Sure If Delta Is Deadlier – The Atlantic

 

Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms.

30 Jun, 2021 | 10:24h | UTC

Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms – Frontiers in Microbiology

 

Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.

30 Jun, 2021 | 10:22h | UTC

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military – JAMA Cardiology

See also: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology

Editorials: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines AND Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working

Commentary: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD

Related: CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

 

Commentary on Twitter

 

Exclusive-WHO estimates COVID-19 boosters needed yearly for most vulnerable.

30 Jun, 2021 | 10:17h | UTC

Exclusive-WHO estimates COVID-19 boosters needed yearly for most vulnerable – Reuters

Related: CDC group says there isn’t enough data yet to recommend Covid booster shots – CNBC

 

Covid: Masks upgrade cuts infection risk, research finds.

30 Jun, 2021 | 10:16h | UTC

Covid: Masks upgrade cuts infection risk, research finds – BBC

 

COVID-19 cut Brazilian life span almost 2 years in 2021.

30 Jun, 2021 | 10:19h | UTC

COVID-19 cut Brazilian life span almost 2 years in 2021 – CIDRAP

Original Study: Reduction in life expectancy in Brazil after COVID-19 – Nature Medicine

 

Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.

30 Jun, 2021 | 10:13h | UTC

Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome – European Heart Journal

 

Consensus Statement: The role of lung ultrasound in COVID-19 disease.

30 Jun, 2021 | 10:12h | UTC

The role of lung ultrasound in COVID-19 disease – Insights into Imaging

 

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

30 Jun, 2021 | 10:11h | UTC

Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta – The Conversation

Related: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv

 

IHME COVID-19 model has been updated for over 200 world locations.

29 Jun, 2021 | 10:13h | UTC

COVID-19 Projections – Institute for Health Metrics and Evaluation

Video: Insights from IHME’s latest COVID-19 model update

 

Commentary on Twitter

 

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

29 Jun, 2021 | 10:09h | UTC

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases

Invited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases

 

Commentary on Twitter

 

SARS-CoV-2 mRNA vaccines induce persistent human germinal center responses, suggesting immunity will be long-lasting.

29 Jun, 2021 | 10:03h | UTC

SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses – Nature

Commentaries: Immune response to FDA-approved vaccines is strong and potentially long-lasting – News Medical

Related: A long-term perspective on immunity to COVID – “Clinical studies now indicate that immunity will be long-lasting”.

 

Commentary on Twitter (thread – click for more)

 

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

29 Jun, 2021 | 10:07h | UTC

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine

Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre

 

[Preprint] 3rd AstraZeneca shot gives strong immunity.

29 Jun, 2021 | 10:01h | UTC

Study: 3rd AstraZeneca shot gives strong immunity – Reuters

Original Study (preprint): Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) – SSRN/The Lancet

 

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

29 Jun, 2021 | 10:00h | UTC

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – Clinical Infectious Diseases

Related: Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

 

The COVID pandemic’s lingering impact on clinical trials – “Medical researchers are beginning to shift their focus away from COVID-19 — but the pandemic could continue to affect studies focused on other diseases.”

29 Jun, 2021 | 09:57h | UTC

The COVID pandemic’s lingering impact on clinical trials – Nature

 

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

28 Jun, 2021 | 10:01h | UTC

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet

Commentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND

 

Commentary on Twitter (thread – click for more)

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.